ABUS
Arbutus Biopharma Corp
4.90$
-3.2%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 7.9% | 818.8% | 1,005.4% | 20.6% | – | 559.7% | 507.9% | 0.1% | 2.1% | 1.0% | 0.0% | – | – | |
| 100.0% | -718.8% | 100.0% | 100.0% | 100.0% | -459.7% | -407.9% | 100.0% | 97.9% | 99.0% | 100.0% | 100.0% | 100.0% | |
| 433.0% | 818.8% | 1,005.4% | 901.0% | 1,065.9% | 559.7% | 507.9% | 51.2% | 1,092.2% | 476.3% | 2.3% | 285.8% | 9.8% | |
| 125.4% | 237.8% | 346.7% | 437.3% | 338.8% | 535.7% | 330.6% | 31.0% | 575.4% | 351.0% | 3.3% | 381.4% | 9.1% | |
| 562.8% | 248.4% | 1,363.9% | 1,350.5% | 1,701.2% | 425.5% | 1,556.9% | 86.1% | 1,665.6% | 826.3% | 5.6% | 688.2% | 19.0% | |
| -462.8% | -967.2% | -1,263.9% | -1,250.5% | -1,601.2% | -885.2% | -1,964.7% | 13.9% | -1,567.7% | -727.3% | 94.4% | -588.2% | 81.0% | |
| 1.0% | 2.1% | 2.9% | 2.0% | 2.2% | 1.9% | 1.6% | 0.3% | 4.3% | 1.7% | 0.0% | 1.8% | 0.0% | |
| -431.6% | -900.3% | -1,166.8% | -1,146.9% | -1,472.5% | -796.2% | -1,390.4% | 23.5% | -1,463.5% | -357.4% | 94.7% | -507.2% | 84.2% | |
| -7.9% | 50.1% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | – | |
| -431.6% | -900.3% | -1,166.8% | -1,146.9% | -1,472.5% | -796.2% | -1,390.4% | 23.5% | -1,463.5% | -357.4% | 94.7% | -507.2% | 84.2% | |
| -422.7% | -939.9% | -1,140.7% | -1,124.3% | -1,445.3% | -974.3% | -1,369.9% | 23.9% | -1,457.1% | -354.6% | 94.8% | -504.3% | 84.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.